LEWIS CENTER, OH / ACCESSWIRE / June 15, 2015 /  Midwest Energy Emissions Corp. (OTCQB: MEEC) (“ME2C” or the “Company”), an emerging leader in mercury emissions control technology for the global coal-power industry, announced today that all holders of the Company’s unsecured 12% Convertible Promissory Notes issued between April 2012 and January 2013 have agreed to extend the maturity dates of the Notes by 12 months from their original maturity dates together with other modifications. The Company reported that it began the process of seeking such amendments from such holders in April 2015. The Company also stated that approximately 1/3 of the principal outstanding as of March 31, 2015 has already been converted into shares of the Company.

Stated President and CEO Richard MacPherson, “Our ability to successfully reach agreement with 100% of the holders of these notes – most of which were originally set to mature during 2015 – demonstrates confidence and support from our early investor base. These notes, which were offered in 2012 and early 2013, had a total principal outstanding of approximately $3.4 million at March 31, 2015 which has now been reduced by over $1.0 million as a result of the recent conversions. We greatly appreciate the continued support of our investors as we focus on our growth initiatives of systems installations, procurement of new business, and entering into what we estimate to be a period of significant business development in the coming twelve months.”

About Midwest Energy Emissions Corp. (ME2C) – Midwest Energy Emissions Corp. delivers patented and proprietary solutions to the global coal-power industry to remove mercury from their power plant emissions, providing performance guarantees and leading edge emissions services. The U.S. Environmental Protection Agency’s (EPA) Mercury and Air Toxic Standards (MATS) rule requires that all coal- and oil-fired power plants in the U.S., larger than 25 mega-watts, must remove roughly 90% of mercury from their emissions starting April 16, 2015. ME2C has developed patented technology and proprietary products that have been shown to achieve mercury removal levels compliant with MATS at a significantly lower cost and with less operational impact than currently used methods, while preserving the marketability of fly-ash for beneficial use.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. Matters that may cause actual results to differ materially from those in the forward-looking statements include, among other factors, the gain or loss of a major customer, additional or new EPA regulations affecting coal-burning utilities, disruption in supply of materials, a significant change in general economic conditions in any of the regions where our customer utilities might experience significant changes in electric demand, a significant disruption in the supply of coal to our customer units, the loss of key management personnel, failure to obtain adequate working capital to execute the business plan and any major litigation regarding the Company. In addition, this release contains time-sensitive information that reflects management’s best analysis only as of the date of this release. The Company does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance related to forward-looking statements contained in this release can be found in the Company’s periodic filings with the Securities and Exchange Commission.

Contact:

Keith R. McGee
Sr. Vice President
Business Development & Investor Relations
Midwest Energy Emissions Corp.
614-505-6115
kmcgee@midwestwemissions.com

SOURCE: Midwest Energy Emissions Corp. 

ReleaseID: 429833

VANCOUVER, BC / ACCESSWIRE / June 15, 2015 / Naturally Splendid Enterprises Ltd. ( “Naturally Splendid” or “NSE”) (FRANKFURT: 50N.F) (TSX VENTURE: NSP) (OTCQB: NSPDF) is pleased to announce it has entered into a definitive securities purchase agreement (the “Purchase Agreement“) with POS Management Corp. (“POS Management” or “POS Bio-Sciences“), a wholly owned subsidiary of POS Holdings Corp. (“POS“), whereby POS Management will sell 51 Class A shares of POS BPC Manufacturing Corp. (“BPC“) to Naturally Splendid and, in consideration of which, Naturally Splendid has agreed to pay CAD $1,750,000 (the “Cash Payment“) to POS Management and will issue 367,647 common shares of Naturally Splendid (the “Consideration Shares“) at a deemed price of $0.68 per share to POS Management. POS Management also agreed that the Consideration Shares will be subject to a trading restriction for a period of 12 months from the date of issue.

On closing of the transaction, Naturally Splendid will own a 51% of BPC, which operates the 12,000 square foot BPC Facility containing approximately 60,000L of tankage, a fractional distillation system, evaporation equipment, spray drying equipment, a ring dryer and various other pieces of complementary & auxiliary equipment owned by BPC. It is capable of processing a variety of products including the suite of plant-based omega technologies such as HempOmega(R) (www.hempomega.com) that Naturally Splendid has licensed from Full Spectrum Laboratories. Additionally, the BPC Facility is designed to produce plant-based extracts, tinctures and dry ingredients for a variety of clients.

POS Bio-Sciences CEO Dale Kelly states, “The BPC Facility was built in the 90’s at a cost of $20,000,000. This facility is of a quality that has the potential to attract world-class clients. It is ISO 9001 certified; has an NHP site license; and is HACCP and cGMP certified; and we are working towards a CFIA site license. Together with Naturally Splendid we will now begin to contact over 600 potential clients to advise them of the services we will offer at the BPC Facility”.

Craig Goodwin, CEO of Naturally Splendid, comments, “The ability for Naturally Splendid to control its own processing is a significant strategic milestone. Once the transaction has closed, we will have secured processing capacity for our own plant-based bio-active ingredients. Additionally, the BPC Facility has the potential to attract a wide range of clients who require toll processing specific to this type of facility. It is anticipated that many of the clients who utilize the research and development services of the POS group of companies will be potential clients of the services at the BPC Facility”.

Pursuant to the terms of the Purchase Agreement, Naturally Splendid will enter into a license and sales agreement with POS Bio-Sciences, whereby Naturally Splendid will have the right to sell and market, on an exclusive basis, five (5) ingredients created using POS Bio-Sciences’ technology (the “Exclusive Products“) and to also sell and market, on a non-exclusive basis, additional ingredients created using POS technologies (the “Non-Exclusive Products“). In consideration of the license, Naturally Splendid has agreed to pay POS a 5% net revenue royalty.

The ingredients included in this licensing arrangement are of high quality sourced plant and marine extracts in the form of powder or oil and will be marketed through Naturally Splendid’s recently launched BC Ingredients (BCI) division (www.bcingredients.com). These ingredients are environmentally sustainable and promote good health and nutrition.

On closing, Naturally Splendid, POS and BPC will also enter into a unanimous shareholders agreement that provides, among other things, equal board representation for each of Naturally Splendid, which will hold 51 Class A shares of BPC, and POS, which will hold 49 Class A Shares of BPC. Dale Kelly, being the President of POS, will serve as Chief Executive Officer of BPC. David Racz, being a director of Naturally Splendid, will be put forward by Naturally Splendid as the initial Chairman of the board of directors, which will require official confirmation by the new Board of Directors of BPC at the first meeting of the Board to be held after the closing of the transaction.

Closing of the transaction is to occur on or before June 19, 2015 and is subject to TSX Venture Exchange acceptance of the transaction.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a multifaceted biotechnology company. The Company is currently innovating in four related industries; 1) nutritional biotechnologies; 2) a retail hemp superfood line under the brand name NATERA(R) and a retail pet care line under the brand name Pawsitive FX(TM); 3) a bulk ingredient division operating under the name BC Ingredients (BCI); 4) and hemp based cannabinoid pharmaceuticals and nutraceuticals.

Naturally Splendid is developing, commercializing, producing, marketing and licensing an entirely new generation of plant-derived, high quality, nutrient-dense foods, nutritional food enhancers, and related products including a suite of plant based omega ingredients. NSP is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of Cannabis Sativa, industrial hemp, and non-psychoactive cannabinoid compounds in a broad spectrum of applications.

These novel products utilize microencapsulation and are available in both a powder format and an aqueous solution for increased flexibility in ingredient applications and stand-alone products. Additionally, Naturally Splendid has licensed the world’s first water soluble cannabinoid patent.

About POS Bio-Sciences (www.pos.ca)

POS Bio-Sciences specializes in the creation of value added products from biological materials, for uses in food supplements, nutraceuticals, cosmetics, biofuels, and medical devices. POS Bio-Sciences provides research and development services to hundreds of companies from around the world who are looking to develop and commercialize processes for extracting, fractionating, modifying, and/or purifying valuable components of biological materials. The facilities used by POS Bio-Sciences allow for on-site analytical testing as well as trials at lab scale, mini-pilot plant scale, and pilot scale. POS Bio-Sciences also provides custom and toll processing services to companies that require a back-up manufacturer, an interim manufacturer while in the process of building their own production facilities, and companies that do not wish to invest in their own production facilities.

All POS Bio-Sciences processes are GMP-compliant and fully supported by quality assurance, commitment to regulatory compliance, and certification to international standards. POS Bio-Sciences also offers a suite of support services to assist clients and ensure that project outcomes meet their needs and expectations.

POS Bio-Sciences is a registered business name of POS Management Corp.

For more information e-mail info@naturallysplendid.com or call 604-673-9573.

On Behalf of the Board of Directors

J. Craig Goodwin

CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N.F Frankfurt)
2435 Beta Avenue
Burnaby, BC, V5C 5N1

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control. There is no guarantee that Naturally Splendid’s plans will be found to be commercially viable; Naturally Splendid will complete the proposed acquisition; Naturally Splendid’s ability to compete with large food and beverage companies; sales of any products developed will be profitable; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.

ReleaseID: 429831

VANCOUVER, BC / ACCESSWIRE / June 15, 2015 / INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC:IVITF; FRA: 8IS) is pleased to announce that it has completed its listing process in the United States on the OTC Markets, and is currently trading under the symbol “IVITF”. In connection with the recent US listing, the Company has also secured DTC eligibility by The Depository Trust Company for its shares

The Depository Trust Company (“DTC”) is a subsidiary of the Depository Trust & Clearing Corporation (“DTCC”), and manages the electronic clearing and settlement of publicly listed securities. Securities that are eligible to be electronically cleared and settled through the DTC are considered ‘DTC Eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.

Brayden Sutton, VP of Business Development commented, “In light of our growing US shareholder base, we are pleased to have our DTC eligible shares trading in the United States. We look forward to providing continued value to both current and prospective shareholders through increased liquidity, lower transaction costs, and increased trading efficiency.”

Invictus MD is also trading in Frankfurt under the symbol 8IS and will continue to trade on the Canadian Securities Exchange under the symbol IMH.

About Invictus MD Strategies Corp.

Invictus MD targets companies with proven brands, strong customer focus, and significant growth potential. We not only provide capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business from start-ups to running large international organizations. The fundamental core of our operations is centered on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic

Chairman & CEO

604-368-6437

SOURCE: Invictus MD Strategies Corp.

ReleaseID: 429832

Upgrades Financial and Corporate Disclosure

JACKSONVILLE, FL / ACCESSWIRE / June 15, 2015 / Information Systems Associates Inc. (“ISA”) (OTCQB: IOSA) and its wholly-owned subsidiary Duos Technologies (“Duos”), a provider of intelligent security analytical technology solutions, has successfully up-listed ISA to the OTCQB Marketplace. ISA Duos core competencies include advanced intelligent technologies that are delivered through its proprietary integrated enterprise command and control platform, centracoTM. The Company provides its broad range of technology solutions with an emphasis on mission critical security, inspection and operations within the rail, utilities, petrochemical, healthcare, and hospitality sectors.

“Following our recent completion of the merger between ISA and Duos, we quickly followed through with our intention to up-list to the OTCQB,” said Gianni Arcaini, Chairman and CEO of ISA and Duos Technologies. “ISA/Duos Technologies is committed to the high level of financial and corporate disclosure that is required for this listing category, which demonstrates our continued commitment to our shareholders. We believe that trading on the OTCQB will raise the visibility of the Company, enhance trading liquidity, and broaden our shareholder base as we move forward with continued market acceptance and penetration of our intelligent security analytical technology solutions.”

The Company plans to build on its successful progression and will continue working towards meeting the listing requirements for trading on a stock exchange such as the NASDAQ in the future.

In 2014, OTC Markets Group introduced standards and eligibility requirements for OTCQB with the goal of making it a better venture marketplace. To be eligible, companies must be current in their reporting to a U.S. or foreign regulator, pass a minimum bid price test of one penny ($0.01) and undergo an annual verification and management certification process providing additional information about the company’s insiders, advisors and share count. Companies that are approved to trade on OTCQB receive access to additional premium services to help them build visibility and improve transparency for investors.

About Information Systems Associates Inc./Duos Technologies Inc.

Information Systems Associates Inc. (OTC Markets: IOSA), based in Jacksonville, FL, provides intelligent security analytical technology solutions with a strong portfolio of intellectual property. Its Duos Technologies’ core competencies include advanced intelligent technologies that are delivered through its proprietary integrated enterprise command and control platform, centracoTM. The Company provides its broad range of technology solutions with an emphasis on mission critical security, inspection and operations within the rail, utilities, petrochemical, healthcare, and hospitality sectors. ISA also offers IT, professional services and consulting services for information technology projects. For more information, check out: http://www.duostechnologies.com.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, the enhanced visibility and liquidity associated with listing on the OTCQB Marketplace, our success in ultimately listing to a national exchange such as NASDAQ and the sufficiency and availability of working capital and general changes in economic conditions. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K for the year ended December 31, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contacts:

Corporate
Jean Martin
904-652-1601
jmm@duostech.com

Investors Relations
Hayden IR
917-658-7878
hart@haydenir.com

SOURCE: Information Systems Associates Inc.

ReleaseID: 429814

NEW YORK, NY / ACCESSWIRE / June 15, 2015 / Heliospectra AB (OTCQB: HLSPY) (FIRSTNORTH: HELIO), a world leader in intelligent lighting technologies for plant research and greenhouse cultivation, is pleased to announce that it will be a featured presenter at the 2015 Major Investment Themes Conference in the Legal Cannabis Track. The conference will be held on June 16, 2015 at the historic Harvard Club in New York City.

The event is New York’s Event for Emerging Microcap Companies and features some of the premier companies in the legal cannabis space. The events is further presented at www.nycapitalexpo.com.

Staffan Hillberg, Heliospectra’s CEO, commented, “Heliospectra is excited to be chosen as one of a select group of companies that is allowed to present to such a high level audience of private and institutional investors.”

About Heliospectra AB:

Heliospectra AB (publ – listed on NASDAQ OMX First North HELIO ISIN SE0005933082 as well as North American ADR OTCQB: HLSPY Cusip: 423281104) (www.heliospectra.com) specializes in intelligent lighting technology for plant research and greenhouse cultivation. Heliospectra products are based on in-depth knowledge in plant physiology and photosynthesis along with a unique way to utilize modern LED technology. After six years of development in Sweden, the company has now begun to expand into the international market. The company has raised more than $15 million in venture capital and has received more than $2.6 million through academic scholarships and grants. It has also received numerous awards for its forward thinking technology. Principal owners: Weland Steel: www.welandstal.se, Swedish Industrial Fund: www.industrifonden.se, Midroc: www.midroc.se ,Wood & Hill Investment: www.whab.se.

Forward-Looking Statements:

The statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties include, but are not limited to, technical advances in the industry as well as political and economic conditions present within the industry. We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.

For more information:

Investor Relations:

Michael Swartz, Analyst
Viridian Capital Advisors, LLC
212-333-0257
mswartz@viridianca.com

Staffan Hillberg, CEO
Heliospectra AB
+46-708-36 59 44
staffan.hillberg@heliospectra.com

SOURCE: Heliospectra AB

ReleaseID: 429818

SAN FRANCISCO, CA / ACCESSWIRE / June 15, 2015 / Accurexa Inc. (the “Company”) (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it has filed a submission with the U.S. Food and Drug Administration (FDA) for 510(k) clearance to market its BranchPoint device.

The Company’s BranchPoint device was invented to deliver therapeutics, such as stem cells, through the radial deployment of a flexible catheter to specific brain target areas through a single brain penetration. The current standard of care is the use of straight, rigid needles, often requiring surgeons to penetrate the brain multiple times for the delivery of therapeutics, which in turn may increase the risk of bleeding, stroke and reflux of therapeutics back out to the brain surface. A study at UCSF* (University of California, San Francisco) demonstrated that the use of a straight needle was associated with reflux of at least 75% of the infusion while no reflux was found with the BranchPoint design. Subsequent studies demonstrated that the BranchPoint device can function with interventional MRI (iMRI) guidance, which may further improve the efficiency of delivery.

“We are excited that we reached this important milestone today. We believe that this accomplishment demonstrates that our team at Accurexa is capable of bringing medical innovations to a regulatory submission to the FDA,” said George Yu, the Company’s President & CEO.

“I want to thank my research team, UCSF and everybody who was involved in this endeavor over the last several years. I also want to thank the California Institute of Regenerative Medicine, which provided nearly $2 million in support for the development of the BranchPoint device. If approved by the FDA, it would enable us to leverage this significant research investment for the clinical treatment of a wide range of diseases of the brain,” said Daniel Lim, MD PhD, who is Associate Professor of Neurological Surgery at UCSF and the lead inventor of the BranchPoint technology.

Notes:

* Silvestrini MT, Yin D, Coppes VG, Mann P, Martin AJ, Larson PS, Starr PA, Gupta N, Panter SS, Desai TA, Lim DA. Radially branched deployment for more efficient cell transplantation at the scale of the human brain. Stereotact Funct Neurosurg. 2013;91(2):92-103.

** Silvestrini MT, Yin D, Martin AJ, Coppes VG, Mann P, Larson PS, Starr PA, Zeng X, Gupta N, Panter SS, Desai TA, Lim DA. Interventional magnetic resonance imaging-guided cell transplantation into the brain with radially branched deployment. Molecular Therapy. 2015;23(1):119-129.

About Accurexa, Inc.

The Company is focused on developing and commercializing novel neurological therapies based on its proprietary BranchPoint device delivering therapeutics directly into specific regions of the brain. The BranchPoint device can deliver therapeutics through the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. Clinicians can “tailor” therapeutic delivery to individual patient anatomy and specific disease targets, which may enhance the efficacy of therapies.

The Company is also developing its ACX-31 program which could deliver temozolomide, a chemotherapy drug, directly to brain cancer sites with its BranchPoint device. Temozolomide is a generic, approved, first-line chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Before temozolomide became generic, it generated US sales of $420 million and global sales of $910 million under its brand name Temodar in 2012. However, current standard of care of delivering temozolomide to tumor sites through oral administration is limited by the blood-brain-barrier and orally administered temozolomide increases patient survival by a significant but modest 2.5 months from a 12.1 months median overall survival. Additional information about the Company may be found on its website, www.accurexa.com.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the ability of the Company to successfully file its 510(k) submission to the FDA, to successfully develop and commercialize novel neurological therapies based on its BranchPoint device and its ACX-31 program, and execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Contact Investor Relations:

Capital Group Communications
575 Bridgeway, Sausalito CA 94965

Mark Bernhard
Tel: 415-332-7200
mark@cgcone.com

Mark Gundy
Tel: 972-240-1873
markgundy@gmail.com

Accurexa Inc.
info@accurexa.com
Tel.: 415-494-7850

SOURCE: Accurexa, Inc.

ReleaseID: 429804

SAN ANTONIO, TX / ACCESSWIRE / June 15, 2015 / Wytec International, a subsidiary of Competitive Companies Inc. (PINKSHEETS: CCOP), announced today it has received an independent “valuation” study of its core business driven by the Company’s unique millimeter wave backhaul design called the “Diamond Ring.” Wytec uses millimeter wave frequencies (60, 70 and 80 GHz) which are quickly becoming a focus for the emerging 5G communication network. “We are extremely pleased with the results of this independent valuation study,” comments William Gray, CEO of Wytec. Wytec commissioned the study to facilitate the due diligence process associated with a proposed financing of $7.5 Million by Unified Business Technologies, Inc. (UBT). UBT is currently in negotiations with Wytec to conclude it definitive agreement involving the financing of 27 markets. Signals Analytics, LLC, the author of the study, used ten-year revenue, operating expense, and capital assumptions (mostly KPI driven) provided by the company to develop a fully valued forward-looking view of the business. The study assumes that Wytec will achieve important operational milestones and that it will be able to secure the growth capital required for its future expansion.

While the valuation includes only Wytec core revenue, it assumes the successful launch of WyQuote, Capaciti’s proprietary agent quoting platform. The study produces a valuation that is significantly higher than the price utilized in the Series B offering in part because of its very inclusive ten-year timeframe and its assumption that the company will ultimately be able to execute on all parts of its business plan.

The study will be utilized by institutional and accredited investors as an input to the due-diligence process associated with Wytec’s current Series B Private Placement. The study was completed on May 28th 2015. CCI, the parent company to Wytec and has now retained Signals Analytics to expand the study to include financials from other Wytec and CCI businesses and to develop a business and deployment framework for Wytec’s patent pending LPN-16 technology.

Recently, Wytec signed a non-binding MOU with Unified Business Technologies, Inc. for $7.5 million in project financing to assist in the build out of its remaining 27 cities under its Master Service Agreement with Level 3 Communications. The Signals Analytics, LLC study included the projected build-out of 174 Tier One, Tier Two and Tier Three U.S. markets over the next five years, and the associated revenue over the next ten years. These markets are expected to generate revenues through the sale of commercial Internet services by Wytec’s sister company, Capaciti Networks, Inc., also a subsidiary of CCI. Capaciti and will market and sell commercial Internet services to the SME market and pay Wytec a percentage of the gross sales for use of the Wytec millimeter wave network. To learn more about Wytec’s Series B Offering, go to www.wytec.biz/ppm.

Please be advised that the valuation study is an estimate only based on assumptions made by management that may prove to be incorrect, including assumptions regarding available capital and financing. There is no assurance that the actual fair market value of Wytec will be equal to the value estimated in the study, and there is a risk that it could be less.

THE INFORMATION IN THIS RELEASE IS NOT AN OFFER TO SELL NOR A SOLICITATION TO BUY ANY SECURITY OF THE COMPANY. ANY OFFER TO SELL OR SOLICITATION TO PURCHASE A SECURITY MAY ONLY BE MADE BY THE COMPLETE CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM FOR THE COMPANY, WHICH INCLUDES A DESCRIPTION OF RISK IMPORTANT RISK FACTORS.

About Wytec International, Inc.:

Wytec, a subsidiary of Competitive Companies, Inc., was founded in 2011 as a Nevada-based corporation with corporate offices in San Antonio, Texas. The Company’s primary business focus is developing next generation fixed and mobile wireless broadband technologies in support of the upcoming 5th Generation (5G) Networks designed to supplement the current 4G LTE Networks. 5G Networks are aimed to support a minimum of one (1) gigabit of data transfer to fixed and mobile wireless end users utilizing a variety of hand-held smart devices such as smartphones, laptops and tablets. It is also designed to support Machine to Machine (M2M) applications and high speed services included in the upcoming “Internet of Things” mobile data marketplace.

About Unified Business Technologies, Inc.:

Unified Business Technologies, Inc. (UBT) is an award-winning, 8(a) certified, woman-and minority-owned business enterprise headquartered in Troy, Michigan. UBT provides Engineering, IT, Wireless Telecommunications, Professional and Administrative, and Construction solutions to the commercial sector as well as the U.S. federal, state, and local governments. Since our foundation in 1997, we have developed an extensive portfolio of experience delivering to our clients timely, cost-effective, and bottom-line driven solutions – integral elements of the modern marketplace that facilitate mission accomplishment. We strive to redefine the standards of excellence in the commercial and government contracting arenas. For more information go to www.ubtus.com.

Forward-Looking Statements:

This press release contains statements that are “forward-looking” and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. Generally, the words “expect,” “intend,” “estimate,” “will” and similar expressions identify forward-looking statements. Since forward-looking statements address future conditions, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made.

CONTACT:

Erica Perez
Media Relations
Email eperez@cci-us.com
Website www.cci-us.com

SOURCE: Competitive Companies, Inc.

ReleaseID: 429807